Status:
NOT_YET_RECRUITING
Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB
Lead Sponsor:
Second Affiliated Hospital of Xi'an Jiaotong University
Collaborating Sponsors:
First Affiliated Hospital Xi'an Jiaotong University
Shaanxi Provincial People's Hospital
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer worldwide, characterized by complex and variable disease progression and significant treatment challenges. Among ...
Eligibility Criteria
Inclusion
- Age is ≥18 years old, male or female;
- Histologically confirmed as hepatocellular carcinoma without metastasis;
- Tumor budding is positive
- Life expectancy of at least 12 weeks;
Exclusion
- Hepatocellular carcinoma that cannot be surgically resected
- Received radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. before surgery
- Pregnant or lactating women
- Subjects with other malignant tumors;
- Subjects who are considered unsuitable to participate in this cohort study by the investigator;
- Subjects who refuse to enroll or do not sign the informed consent form;
- Subjects with incomplete medical record information (including gender, age, diagnostic information, imaging (and) or pathological diagnosis results, other demographic data, etc.).
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT07160361
Start Date
October 1 2025
End Date
December 31 2029
Last Update
September 16 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.